Literature DB >> 32288914

Non-animal replacement methods for veterinary vaccine potency testing: state of the science and future directions.

Jodie Kulpa-Eddy1, Geetha Srinivas2, Marlies Halder3, Richard Hill2, Karen Brown4, James Roth5, Hans Draayer6, Jeffrey Galvin6, Ivo Claassen7, Glen Gifford8, Ralph Woodland9, Vivian Doelling10, Brett Jones10, William S Stokes11.   

Abstract

NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. Six topics were addressed in detail by speakers and workshop participants and are reported in a series of six reports. This workshop report, the second in the series, provides recommendations for current and future use of non-animal methods and strategies for veterinary vaccine potency testing. Workshop participants recommended that future efforts to replace animal use give priority to vaccines (1) that use large numbers of animals per test and for which many serials are produced annually, (2) that involve significant animal pain and distress during procedures, (3) for which the functional protective antigen has been identified, (4) that involve foreign animal/zoonotic organisms that are dangerous to humans, and (5) that involve pathogens that can be easily spread to wildlife populations. Vaccines identified as the highest priorities were those for rabies, Leptospira spp., Clostridium spp., Erysipelas, foreign animal diseases (FAD), poultry diseases, and fish diseases. Further research on the identification, purification, and characterization of vaccine protective antigens in veterinary vaccines was also identified as a priority. Workshop participants recommended priority research, development, and validation activities to address critical knowledge and data gaps, including opportunities to apply new science and technology. Recommendations included (1) investigations into the relative impact of various adjuvants on antigen quantification assays, (2) investigations into extraction methods that could be used for vaccines containing adjuvants that can interfere with antigen assays, and (3) review of the current status of rabies and tetanus human vaccine in vitro potency methods for their potential application to the corresponding veterinary vaccines. Workshop participants recommended enhanced international harmonization and cooperation and closer collaborations between human and veterinary researchers to expedite progress. Implementation of the workshop recommendations is expected to advance alternative in vitro methods for veterinary vaccine potency testing that will benefit animal welfare and replace animal use while ensuring continued protection of human and animal health.
Copyright © 2012 Published by Elsevier B.V.

Entities:  

Keywords:  ICCVAM; replacement alternatives; vaccine potency testing; vaccine safety testing; veterinary vaccines

Year:  2011        PMID: 32288914      PMCID: PMC7129755          DOI: 10.1016/j.provac.2011.10.005

Source DB:  PubMed          Journal:  Procedia Vaccinol


  38 in total

1.  Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use.

Authors:  B Krämer; L Bruckner; A Daas; C Milne
Journal:  Pharmeur Bio Sci Notes       Date:  2010-10

2.  The current state of vaccines used in the field for foot and mouth disease virus in China.

Authors:  Zhiyong Li; Jixing Liu
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

3.  Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM workshop 48.

Authors:  Lukas Bruckner; Klaus Cussler; Marlies Halder; Jacques Barrat; Peter Castle; Karin Duchow; Donna M Gatewood; Richard Gibert; Jan Groen; Bernhard Knapp; Robin Levis; Catherine Milne; Simon Parker; Karin Stünkel; Nico Visser; Peter Volkers
Journal:  Altern Lab Anim       Date:  2003-09       Impact factor: 1.303

4.  An in vitro immune response model to determine tetanus toxoid antigen (vaccine) specific immunogenicity: Selection of sensitive assay criteria.

Authors:  Sytse J Piersma; Marlies P P A M Leenaars; Laurence Guzylack-Piriou; Artur Summerfield; Coenraad F M Hendriksen; Ken C McCullough
Journal:  Vaccine       Date:  2006-02-13       Impact factor: 3.641

5.  The potential of physicochemical and immunochemical assays to replace animal tests in the quality control of toxoid vaccines. The report and recommendations of ECVAM workshop 61.

Authors:  Bernard Metz; Florence Brunel; Catherine Chamberlin; Johan van der Gun; Marlies Halder; Wim Jiskoot; Gideon Kersten; Omer van Opstal; Jesper W Petersen; Satish D Ravetkar; Keith Redhead; Michael Schwanig; Ellen Sloth Wilhelmsen; Willie F Vann; Coenraad Hendriksen
Journal:  Altern Lab Anim       Date:  2007-06       Impact factor: 1.303

Review 6.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 7.  Options for control of foot-and-mouth disease: knowledge, capability and policy.

Authors:  David J Paton; Keith J Sumption; Bryan Charleston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-09-27       Impact factor: 6.237

8.  Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.

Authors:  Marvin J Grubman
Journal:  Biologicals       Date:  2005-11-14       Impact factor: 1.856

9.  The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines.

Authors:  B Krämer; H Schildger; H A Behrensdorf-Nicol; K M Hanschmann; K Duchow
Journal:  Biologicals       Date:  2009-01-31       Impact factor: 1.856

10.  Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice.

Authors:  Peter S Wunderli; David W Dreesen; Timothy J Miller; George M Baer
Journal:  Am J Vet Res       Date:  2003-04       Impact factor: 1.156

View more
  2 in total

1.  Replacement of in vivo leptospirosis vaccine potency testing in the United States.

Authors:  Bridget Rogers; Jeffrey Brown; David G Allen; Warren Casey; Amy J Clippinger
Journal:  Biologicals       Date:  2022-06-24       Impact factor: 1.760

2.  Non-animal replacement methods for veterinary vaccine potency testing: state of the science and future directions.

Authors:  Jodie Kulpa-Eddy; Geetha Srinivas; Marlies Halder; Richard Hill; Karen Brown; James Roth; Hans Draayer; Jeffrey Galvin; Ivo Claassen; Glen Gifford; Ralph Woodland; Vivian Doelling; Brett Jones; William S Stokes
Journal:  Procedia Vaccinol       Date:  2011-12-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.